High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity.

Alessia Garufi,Gabriella D’Orazi

doi:10.1186/s13046-014-0079-4

Abstract

BackgroundIn response to diverse genotoxic stimuli p53 is activated as transcription factor to exert its tumor-suppressor function. P53 activation requires protein stabilization, nuclear localization and posttranslational modifications in key residues that may influence p53 selection of target genes. Among them, serine 46 (Ser46) phosphorylation is considered specific for apoptotic activation. Hyperglicaemia, the high blood glucose condition, may negatively affect tumor response to therapies through several mechanisms, conferring resistance to drug-induced cell death. However, whether high glucose might modify p53Ser46 phosphorylation has never been addressed.Methods and resultsHere, we performed biochemical and molecular analyses in different cancer cell lines treated with chemotherapy in the presence or absence of high glucose condition. Analyses of p53 posttranslational modifications showed that drug-induced p53Ser46 phosphorylation was reduced by high glucose. Such reduction depended by high glucose-induced calyculin A-sensitive phosphatase(s), able to specifically target p53Ser46 phosphorylation. The specific effect on Ser46 phosphorylation was addressed by analysing Ser15 phosphorylation that instead was not modified by high glucose. In agreement, a constitutively phosphorylated Ser46D p53 mutant was resistant to high glucose. As a consequence of phosphoSer46 impairment, high glucose reduced the tumor cell response to drugs, correlating with reduced p53 apoptotic transactivation. The drug-induced apoptotic cell death, reduced by high glucose, was finally restored by the phosphatase inhibitor calyculin A.ConclusionsThese data indicate that high glucose specifically inhibited Ser46 phosphorylation thus reducing p53 apoptotic activity. These results uncover a new mechanism of p53 inactivation providing an interesting novel molecular link between metabolic diseases such as diabetes or obesity and tumor progression and resistance to therapies.

Highlights

In response to diverse genotoxic stimuli p53 is activated as transcription factor to exert its tumor-suppressor function
Glucose reduces chemotherapy-induced cell death To look into the influence of high glucose (HG) levels on resistance to chemotherapeutic agents, several human cancer cells, carrying wild-type p53, including RKO and HCT116 colon cancer, 2008 ovarian cancer and A549 lung cancer cells, were incubated with chemotherapeutic drugs, such as adryamicin (ADR) or cisplatin (CDDP), before or after treatment with HG (4.5 g/L Dglucose) condition
Cancer cell death induced by apoptotic doses of chemotherapy, as previously reported [10,31], was significantly reduced when cells were transferred into HG culture condition (Figure 1A)

Summary

Introduction

In response to diverse genotoxic stimuli p53 is activated as transcription factor to exert its tumor-suppressor function. In response to several types of genotoxic stress p53 is activated to control genes that lead to different cellular outcome such as cell-cycle arrest and apoptosis. In this manner, p53 protects cells from tumorigenesis, reduces tumor progression, and activates tumor cell response to anticancer drugs [2]. A mutant active form of p53, in which Ser is replaced with phenylalanine (p53-46 F), has been shown to induce apoptosis more effectively that wild-type (wt) p53 [16], while studies with knock-in mice expressing the human TP53 gene with Ser46A mutation (non phosphorylatable Ser46), reduced p53 apoptotic transactivation [17], strengthening the apoptotic role for this p53 posttranslational modification

Methods

Results

Conclusion